EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation

Kazutaka Hosoya iD, Hiroaki Ozasa iD, Hironori Yoshida, Hitomi Ajimizu, Takahiro Tsuji iD, Masatoshi Yamazoe, Tatsuya Ogimoto, Kentaro Hashimoto, Tomoko Funazo Yamamoto, Keiichiro Suminaga, Yusuke Shima, Hiroshi Yoshida und 8 weitere

Cancer Science · 2025

DOI: 10.1111/cas.70075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Kazutaka Hosoya und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Survivin, Imidazoles, Transcription Factors. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Support for Pioneering Research Initiated by the Next Generation, Takeda Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The BRAF V600E mutation is observed in 2% of the patients with lung adenocarcinoma (LUAD), and combination therapy targeting BRAF and mitogen‐activated protein kinase (MEK) is the standard treatment for this population. However, acquired resistance inevitably develops, which highlights the need for novel therapeutic strategies. In this study, we established a patient‐derived BRAF V600E‐mutated LUAD cell line, KTOR81, and investigated the potential of targeting the Yes‐associated protein 1 (YAP1)/transcriptional enhanced associate domain 1 (TEAD1) pathway in combination with BRAF inhibition. We observed that the novel TEAD1 inhibitor VT103 enhanced the efficacy of the BRAF inhibitor dabrafenib in KTOR81 cells and xenograft models. The combination of dabrafenib and VT103 downregulated the expression of the antiapoptotic protein survivin, which is transcriptionally regulated by the YAP1/TEAD1 complex, leading to increased apoptosis. Moreover, we used a LUAD tissue microarray to compare the staining patterns of YAP1, TEAD1, and survivin, and examined their association with prognosis. These analyses revealed a strong correlation between YAP1, TEAD1, and survivin expression in LUAD, suggesting the relevance of the YAP1/TEAD1‐survivin axis beyond BRAF V600E‐mutated cases. While no statistically significant association was observed between survivin expression and prognosis, when limited to driver oncogene‐positive patients, high survivin expression was suggested to be associated with poor prognosis. These findings provide preclinical evidence for the efficacy of combining TEAD1 inhibition with BRAF‐targeted therapy in BRAF V600E‐mutated LUAD and highlight the YAP1/TEAD1‐survivin axis as a potential therapeutic target especially in the driver oncogene‐positive LUAD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafSurvivinImidazolesTranscription FactorsAdenocarcinoma of LungLung NeoplasmsDNA-Binding ProteinsOximesNuclear ProteinsAntineoplastic Combined Chemotherapy ProtocolsHumansAnimalsTEA Domain Transcription FactorsXenograft Model Antitumor AssaysCell Line, TumorMiceMutationDown-RegulationYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingApoptosisFemaleGene Expression Regulation, NeoplasticMaleMice, NudePrognosisDrug SynergismNaphthoquinones

Stichwörter der Autor:innen

BRAF V600ETEAD1YAP1lung cancersurvivin

Substanzen

Proto-Oncogene Proteins B-rafSurvivinImidazolesTranscription FactorsTEA Domain Transcription FactorsdabrafenibTEAD1 protein, humanDNA-Binding ProteinsBRAF protein, humanOximes

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Anatomy and Molecular Cell Biology, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
  • Department of Diagnostic Pathology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Diagnostic Pathology, Graduate School of Medicine, Nara Medical University, Nara, Japan.

ORCID-Profile: Kazutaka Hosoya, Hiroaki Ozasa, Takahiro Tsuji

Förderung

  • Japan Society for the Promotion of Science
  • Support for Pioneering Research Initiated by the Next Generation
  • Takeda Science Foundation

Zitieren

APA

Hosoya, K., Ozasa, H., Yoshida, H., Ajimizu, H., Tsuji, T., Yamazoe, M., Ogimoto, T., Hashimoto, K., Funazo Yamamoto, T., Suminaga, K., Shima, Y., Yoshida, H., Nomizo, T., Ito, H., Terada, K., Nishikawa, S., Menju, T., Yoshizawa, A., Date, H., & Hirai, T. (2025). Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation. Cancer Science. https://doi.org/10.1111/cas.70075

Vancouver

Hosoya K, Ozasa H, Yoshida H, Ajimizu H, Tsuji T, Yamazoe M, et al. Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation. Cancer Science. 2025. doi:10.1111/cas.70075

BibTeX
@article{Hosoya2025,
  author = {Hosoya, Kazutaka and Ozasa, Hiroaki and Yoshida, Hironori and Ajimizu, Hitomi and Tsuji, Takahiro and Yamazoe, Masatoshi and Ogimoto, Tatsuya and Hashimoto, Kentaro and Funazo Yamamoto, Tomoko and Suminaga, Keiichiro and Shima, Yusuke and Yoshida, Hiroshi and Nomizo, Takashi and Ito, Hiroaki and Terada, Kazuhiro and Nishikawa, Shigeto and Menju, Toshi and Yoshizawa, Akihiko and Date, Hiroshi and Hirai, Toyohiro},
  title = {Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation},
  journal = {Cancer Science},
  year = {2025},
  doi = {10.1111/cas.70075}
}
Kostenlos starten →